Clinical Trial Update: GVAX in Advanced Prostate Cancer Patients Made Lymphopenic [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial update of GVAX in advanced prostate cancer notes that patients became lymphopenic, indicating a potential safety concern.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• GVAX

Snippet

Sponsor: Providence Health & Services | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN